Today, our team is focused on a single goal: To develop the first oral drug for eosinophilic asthma.Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.